Trial Profile
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Acute myeloid leukaemia; CNS cancer; Diffuse intrinsic pontine glioma; Ewing's sarcoma; Glioma; Leukaemia; Nerve sheath neoplasms; Neurofibromatosis 1; Plexiform neurofibroma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- 12 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 12 Sep 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 10 Nov 2022 Planned number of patients changed from 81 to 54.